CD47 and neoplasm: Pioneering studies identified B6H12, a function-blocking anti-CD47 monoclonal antibody (mAb) that can inhibit the binding of two endogenous partners, SIRPα and the secreted glycoprotein Thrombospondin-1 (Tsp-1); B6H12 showed efficacy in pre-clinical tumor models and hematological malignancies2,8–13.